Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 26

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 26
---
 of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve environmental, social and governance goals; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. We caution investors to consider carefully these factors. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in our 2024 Form 10-K, this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or therein.

For a discussion of important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements, see Part I, Item 1A. under the heading “Risk Factors” in our 2024 Form 10-K, and under the heading “Risk Factors” herein, in the accompanying prospectus and in any other document we may file with the SEC that is incorporated by reference herein and therein.

<div align='center'>S-12</div>

TABLE OF CONTENTS

### USE OF PROCEEDS
We estimate the net proceeds from this offering will be approximately €1,487 million after deducting the underwriting discounts and offering expenses payable by us. We intend to use the net proceeds from this offering, together with cash on hand, to fund the repayment at maturity of the March 2025 Notes, of which €1,000 million aggregate principal amount was outstanding as of the date of this prospectus supplement, and to pay accrued and unpaid interest with respect to such notes, and for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.

Certain of the underwriters or their affiliates may hold March 2025 Notes. To the